ValuEngine Lowers Oramed Pharmaceuticals (ORMP) to Sell
Oramed Pharmaceuticals (NASDAQ:ORMP) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a report released on Tuesday.
Separately, HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of Oramed Pharmaceuticals in a report on Thursday, October 5th.
Shares of Oramed Pharmaceuticals (NASDAQ:ORMP) traded down $0.77 during midday trading on Tuesday, hitting $7.94. 240,448 shares of the stock were exchanged, compared to its average volume of 43,205. Oramed Pharmaceuticals has a 1-year low of $5.82 and a 1-year high of $11.34.
COPYRIGHT VIOLATION NOTICE: This piece of content was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/05/valuengine-lowers-oramed-pharmaceuticals-ormp-to-sell.html.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Oramed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.